medigraphic.com
Instituto Nacional de Salud Pública

2021, Número 6

<< Anterior Siguiente >>

salud publica mex 2021; 63 (6)


Seroprevalencia de SARS-CoV-2 en adultos y adultos mayores en México y su asociación con enfermedades crónicas. Ensanut 2020 Covid-19

Sánchez-Pájaro A, Pérez-Ferrer C, Basto-Abreu A, Rivera-Dommarco J, Barquera S, Denova-Gutiérrez E, Barrientos-Gutiérrez T

Idioma: Español
Referencias bibliográficas: 21
Paginas: 705-712
Archivo PDF: 291.42 Kb.


RESUMEN

Objetivo. Analizar la asociación entre seropositividad a SARS-CoV-2 y enfermedades crónicas en adultos y adultos mayores mexicanos. Material y métodos. Se utilizó la Encuesta Nacional de Salud y Nutrición 2020 sobre Covid-19 (Ensanut 2020 Covid-19) para evaluar la asociación de seropositividad a SARS-CoV-2 con hipertensión arterial sistémica, diabetes tipo 2, índice de masa corporal, LDL-c elevado, HDL-c bajo, colesterol total elevado e hipertrigliceridemia. Resultados. Se observó una mayor seropositividad en personas con mayor índice de masa corporal. La seroprevalencia fue 25% mayor entre los adultos que presentaban obesidad en comparación con aquellos de peso normal en modelos ajustados (RP: 1.25 IC95%: 1.08,1.46). No se observó asociación entre seropositividad y otras enfermedades crónicas en adultos o adultos mayores. Conclusiones. Las personas con obesidad podrían tener una mayor susceptibilidad a la infección por SARS-CoV-2. Este hallazgo debe ser confirmado con estudios longitudinales. No se encontró evidencia de asociación para otras enfermedades.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gao F, Zheng KI, Wang X-B, Sun Q-F, Pan K-H, Wang T-Y, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43(7):e72-4. https://doi.org/10.2337/dc20-0682

  2. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5. https:// doi.org/10.1016/j.ijid.2020.03.017

  3. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1-4. https://doi.org/10.1172/ jci92035

  4. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128. https://doi.org/10.1111/obr.13128

  5. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metabolism. 2021;33(3):479-98. https://doi. org/https://doi.org/10.1016/j.cmet.2021.01.016

  6. Lontchi-Yimagou E, Feutseu C, Kenmoe S, Djomkam-Zune AL, Kinyuy- Ekali SF, Nguewa JL, et al. Non-autoimmune diabetes mellitus and the risk of virus infections: a systematic review and meta-analysis of case-control and cohort studies. Scientific reports. 2021;11(1):8968. https://doi. org/10.1038/s41598-021-88598-6

  7. Chan CK, Huang YS, Liao HW, Tsai IJ, Sun CY, Pan HC, et al. Reninangiotensin- aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. Hypertension. 2020;76(5):1563-71. https://doi.org/10.1161/ hypertensionaha.120.15989

  8. Accorsi EK, Qiu X, Rumpler E, Kennedy-Shaffer L, Kahn R, Joshi K, et al. How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and Covid-19. Eur J Epidemiol. 2021;36(2):179-96. https://doi. org/10.1007/s10654-021-00727-7

  9. Schlesinger S, Neuenschwander M, Lang A, Pafili K, Kuss O, Herder C, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021;64(7):1480-91. https://doi.org/10.1007/s00125-021-05458-8

  10. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunol. 2020; 5(54):eabe0240. https://doi.org/10.1126/sciimmunol.abe0240

  11. Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista- Arredondo S, Colchero A, Gaona-Pineda EB, et al. Metodología de la Encuesta Nacional de Salud y Nutrición 2020 sobre Covid-19. Salud Publica Mex. 2021;63(3):444-51. https://doi.org/10.21149/12580

  12. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(supl 1):S15. https://doi.org/10.2337/dc21-S002

  13. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082- 143. https://doi.org/10.1161/CIR.0000000000000625

  14. Deaton A, Zaidi S. Guidelines for constucting comsumption aggregates for welfare analysis. Washington DC: The World Bank, 2002.

  15. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID- 19 outcomes in Mexico. J Clin Endocrinol Metab. 2020;105(8):2752- 61. https://doi.org/10.1210/clinem/dgaa346

  16. Antonio-Villa NE, Bello-Chavolla OY, Vargas-Vázquez A, Fermín- Martínez CA, Márquez-Salinas A, Bahena-López JP. Health-care workers with COVID-19 living in Mexico City: clinical characterization and related outcomes. Clin Infect Dis. 2020;73(1):e191-8. https://doi.org/10.1093/cid/ ciaa1487

  17. Denova-Gutiérrez E, Lopez-Gatell H, Alomia-Zegarra JL, López-Ridaura R, Zaragoza-Jimenez CA, Dyer-Leal DD, et al. The Association of obesity, type 2 diabetes, and hypertension with severe coronavirus disease 2019 on admission among Mexican patients. Obesity. 2020;28(10):1826-32. https://doi.org/https://doi.org/10.1002/oby.22946

  18. Basto-Abreu A, Barrientos-Gutiérrez T, Rojas-Martínez R, Aguilar- Salinas CA, López-Olmedo N, De la Cruz-Góngora V, et al. Prevalence of diabetes and poor glycemic control in Mexico: results from Ensanut 2016. Salud Publica Mex. 2020; 62(1):50-9. https://doi.org/10.21149/10752

  19. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Med. 2020;26(8):1200-04. https://doi.org/10.1038/s41591-020-0965-6

  20. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Med. 2020;26(6):845-8. https://doi.org/10.1038/s41591-020-0897-1

  21. Barquera S, Rivera JA. Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies. Lancet Diabetes Endocrinol. 2020;8(9):746-7. https://doi.org/10.1016/S2213-8587(20)30269-2




2020     |     www.medigraphic.com